









市場行情
/
股票
/
nasdaq-lptx
/

Leap Therapeutics Inc

LPTX

2.050USD

0.000

收盤 12/19, 16:00（美東）報價延遲15分鐘

84.95M總市值

虧損本益比TTM



Leap Therapeutics Inc

2.050

0.000

概覽公司財務分析

概覽

公司

財務

分析

關於 Leap Therapeutics Inc 公司

Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways. The Company’s lead clinical stage drug candidate is sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. The Company is developing DKN-01 in a clinical trial in patients with colorectal cancer and has also conducted clinical trials in patients with gastric/gastroesophageal junction cancer and endometrial cancer patients. The Company also has a preclinical program to develop a proprietary monoclonal antibody known as FL-501. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.

Leap Therapeutics Inc簡介



公司代碼LPTX

公司名稱Leap Therapeutics Inc

上市日期Jan 24, 2017

CEOOnsi (Douglas E)

員工數量52

證券類型Ordinary Share

年結日Jan 24

公司地址47 Thorndike Street

城市CAMBRIDGE

上市交易所NASDAQ Capital Market Consolidated

國家United States of America

郵編02142

電話16172524343

網址https://www.leaptx.com/

公司代碼LPTX

上市日期Jan 24, 2017

CEOOnsi (Douglas E)

Leap Therapeutics Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Douglas E. (Doug) Onsi

President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director

140.87K

+30.09%

Dr. Christopher K. Mirabelli, Ph.D.

Director

23.05K

Ms. Christine Granfield

Vice President, Head - Regulatory Affairs and Quality

15.90K

Dr. Jason Baum, Ph.D.

Chief Scientific Officer

15.90K

Dr. James H. Cavanaugh, Ph.D.

Independent Director

214.00

Mr. Khing Oei

Independent Chairman of the Board

Mr. William (Wil) Mcevoy

Chief Investment Officer, Director

Dr. Richard L. Schilsky, M.D.

Independent Director

Dr. Joseph Loscalzo, M.D., Ph.D.

Independent Director

Dr. William W. Li, M.D.

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Mr. Douglas E. (Doug) Onsi

President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director

140.87K

+30.09%

Dr. Christopher K. Mirabelli, Ph.D.

Director

23.05K

Ms. Christine Granfield

Vice President, Head - Regulatory Affairs and Quality

15.90K

Dr. Jason Baum, Ph.D.

Chief Scientific Officer

15.90K

Dr. James H. Cavanaugh, Ph.D.

Independent Director

214.00

Mr. Khing Oei

Independent Chairman of the Board

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 7 小時前

持股股東

股東類型

持股股東

佔比

Winklevoss Capital Management, LLC

14.62%

Severns (Sean Michael)

10.59%

Gilead Sciences Inc

9.39%

BofA Global Research (US)

2.55%

Acadian Asset Management LLC

2.18%

其他

60.66%

持股股東

佔比

Winklevoss Capital Management, LLC

14.62%

Severns (Sean Michael)

10.59%

Gilead Sciences Inc

9.39%

BofA Global Research (US)

2.55%

Acadian Asset Management LLC

2.18%

其他

60.66%

股東類型

持股股東

佔比

Family Office

14.62%

Corporation

11.53%

Individual Investor

10.99%

Investment Advisor

6.90%

Investment Advisor/Hedge Fund

3.10%

Research Firm

2.88%

Venture Capital

1.25%

Hedge Fund

0.35%

Bank and Trust

0.01%

其他

48.38%

機構持股



更新時間: 10月5日週日

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

109

9.06M

16.46%

-11.77M

2025Q2

120

18.70M

45.12%

-8.55M

2025Q1

140

18.85M

45.62%

-6.95M

2024Q4

134

21.35M

55.72%

-2.16M

2024Q3

140

20.83M

54.42%

+2.16M

2024Q2

141

20.87M

54.74%

+4.28M

2024Q1

149

9.36M

39.74%

-1.79M

2023Q4

154

7.72M

34.00%

-3.79M

2023Q3

169

9.36M

44.45%

-1.96M

2023Q2

173

10.09M

52.77%

+1.83M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Gilead Sciences Inc

5.32M

12.84%

Jun 30, 2025

Acadian Asset Management LLC

1.24M

2.99%

-43.42K

-3.39%

Jun 30, 2025

Beigene Ltd

1.22M

2.93%

+1.22M

Oct 31, 2024

The Vanguard Group, Inc.

1.16M

2.8%

-14.92K

-1.27%

Jun 30, 2025

Hightower Advisors, LLC

1.10M

2.65%

+1.05M

+2071.98%

Jun 30, 2025

Simplify Asset Management Inc

857.36K

2.07%

-93.61K

-9.84%

Jun 30, 2025

HealthCare Ventures LLC

697.23K

1.68%

+20.91K

+3.09%

Apr 21, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Simplify Health Care ETF

0.37%

iShares Micro-Cap ETF

Dimensional US Core Equity 1 ETF

DFA Dimensional US Sustainability Core 1 ETF

Avantis US Small Cap Equity ETF

Simplify Health Care ETF

佔比0.37%

iShares Micro-Cap ETF

佔比0%

Dimensional US Core Equity 1 ETF

佔比0%

DFA Dimensional US Sustainability Core 1 ETF

佔比0%

Avantis US Small Cap Equity ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

Jun 20, 2023

Merger

10→1

Jun 20, 2023

Merger

10→1

Jun 20, 2023

Merger

10→1

Jun 20, 2023

Merger

10→1

公告日期

類型

比率

Jun 20, 2023

Merger

10→1

Jun 20, 2023

Merger

10→1

Jun 20, 2023

Merger

10→1

Jun 20, 2023

Merger

10→1

常見問題

Leap Therapeutics Inc的前五大股東是誰？



Leap Therapeutics Inc的前五大股東如下：
Gilead Sciences Inc
持有股份：5.32M
佔總股份比例：12.84%。
Acadian Asset Management LLC
持有股份：1.24M
佔總股份比例：2.99%。
Beigene Ltd
持有股份：1.22M
佔總股份比例：2.93%。
The Vanguard Group, Inc.
持有股份：1.16M
佔總股份比例：2.80%。
Hightower Advisors, LLC
持有股份：1.10M
佔總股份比例：2.65%。